News and Trends 24 Aug 2022 Millions in funding and new board members for Belgian mRNA company The mRNA technologies company eTheRNA has raised €39 million ($38.7 million) in series B2 financing. Belgium-based eTheRNA will use the money to expand investment in its integrated mRNA technology platform and further pursue its new initiatives for a partnership-driven business strategy. The round was led by Novalis LifeSciences LLC with participation from Professor Kenneth Chien, […] August 24, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2022 IVI and Moderna sign MOU for vaccine R&D The International Vaccine Institute (IVI), an international organization with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health, and Moderna, a biotech company working on messenger RNA (mRNA) therapeutics and vaccines, have signed a Memorandum of Understanding (MOU) to partner on collaborative vaccine research and development. “IVI welcomes this […] July 20, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jul 2022 Cancer therapeutics company’s double win with $25M funding, and appointment of new board member An mRNA-technology company developing cancer therapeutics designed to improve patients’ survival rate and quality of life — this week announced the completion of a $25 million Series A financing. Kernal Biologics, Inc. (Kernal Bio) confirmed that the funding was led by Hummingbird Ventures. Amgen Ventures, HBM Genomics and Civilization Ventures along with other venture capitalists, family offices and […] July 8, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jul 2022 Exyte Builds mRNA Competence Center for WACKER in Germany A messenger ribonucleic acid (mRNA) competence center is being built at the Halle Biotech site of German company Wacker Chemie AG (WACKER). Exyte GmbH is a global design, engineering company that delivers facilities for high-tech industries and is in charge of the site at WACKER. The project is making a considerable contribution towards strengthening the […] July 6, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
In Depth 4 Jul 2022 The COVID-19 pandemic has driven RNA therapeutics into the mainstream As messenger RNA vaccines save lives around the world, and RNA interference drugs are greenlit for rare diseases, the field of RNA therapeutics is now moving faster than ever before. The COVID-19 pandemic proved a turning point for the biotech companies BioNTech and Moderna, which specialize in developing technology based on messenger RNA (mRNA). The […] July 4, 2022 - 8 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 24 Jun 2022 Covid and malaria vaccines on track for mass production in Rwanda Construction of the first African messenger RNA (mRNA) manufacturing facility has started in Africa. This means Biopharmaceutical New Technologies (BioNTech) SE is a step closer to producing mRNA vaccines that teach human cells how to make a protein that will trigger an immune response inside the body. The company is a next generation immunotherapy company […] June 24, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 21 Jun 2022 New agreement could lead to first African-owned COVID-19 vaccine A year after the creation of the mRNA Vaccine Technology Transfer Hub, two biotech companies – Afrigen Biologics and the Univercells Group – are set to work together. The agreement intends to pave the way for the development of the first African-owned COVID-19 vaccine. The collaboration will focus on the development of a novel mRNA […] June 21, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jun 2022 Eurocine Vaccines expands portfolio to develop HSV-2 vaccine Swedish company Vaccines AB (Eurocine Vaccines) has entered into a research and collaboration agreement with Redbiotec AG. The agreement gives Eurocine Vaccines the exclusive global rights to develop, manufacture and commercialize vaccine candidates against Herpes Simplex Virus Type 2 (HSV-2), based on technologies developed by Swiss biotech company Redbiotec. The agreement covers both an mRNA […] June 15, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jun 2022 Ziphius Vaccines and University of Antwerp to work on RNA-based delivery methods Belgian biopharma firm Ziphius Vaccines is set to collaborate with the University of Antwerp to research and develop a lipid library for optimized delivery systems of self-amplifying RNA-based drugs (saRNA) and therapeutics. Messenger RNA (mRNA) vaccines deliver genetic instructions to cells to create proteins that then train the immune system against a pathogen, such as […] June 9, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 May 2022 Therapeutic RNA company receives additional funding UK biotech company Transine Therapeutics, which is developing a novel class of therapeutic RNAs, has successfully raised £4.6M ($5.8M) in additional seed funding. The financing was led by new investor Epidarex Capital with participation from existing investor the Dementia Discovery Fund (DDF). Transine said the additional funds will enable it to further develop its SINEUP […] May 31, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Feb 2022 Ethris Raises €23M to Make Inhaled Respiratory Therapies from mRNA Thanks to Covid-19 vaccines, messenger RNA (mRNA) technology has reached the mainstream. With a €23.4M Series B round, the German firm Ethris is riding the mRNA buzz by developing inhalable mRNA therapies for respiratory diseases. As Covid-19 mRNA vaccines entered the market for the first time in 2020, the wide potential of mRNA technology became […] February 1, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 17 Aug 2021 Sanofi’s Translate Bio Buyout Shows Growing Hunger for mRNA Technology Sanofi’s acquisition of its partner Translate Bio is a clear sign that pharmaceutical companies are interested in messenger RNA technologies beyond Covid-19. Based in Boston, US, Translate Bio develops mRNA therapies for a range of conditions, including respiratory, liver, and infectious diseases. The company’s €2.7B ($3.2B) buyout, announced by Sanofi earlier this month, seems a […] August 17, 2021 - 5 minutesmins - By Mark Zipkin Share WhatsApp Twitter Linkedin Email